The UPR is an evolutionarily conserved intracellular signaling pathway triggered when unfolded proteins accumulate in the ER^[@R1],[@R2]^. The UPR is believed to be centrally involved in the pathogenesis of numerous cell degenerative disorders, such as diabetes^[@R3]^ and neurodegeneration, and conversely the inappropriate survival of secretory cell tumors, such as multiple myeloma^[@R4]^. Because the UPR normally relegates irremediably ER stressed cells to apoptosis, the ability to control the UPR's cell fate outcomes in both positive and negative directions may provide new therapeutic options for these diseases^[@R5]^. To this end, we have been developing pharmacological tools to both activate and inhibit the master regulator of the UPR, a bifunctional enzyme called IRE1α^[@R6]--[@R9]^.

IRE1α is an ER transmembrane protein that becomes activated when unfolded proteins accumulate within the organelle. Through an N-terminal ER lumenal domain that senses unfolded proteins, IRE1α monomers dimerize and potentially oligomerize in the plane of the ER membrane^[@R10]--[@R12]^. This event juxtaposes cytosolic kinase domains across individual IRE1α monomers, causing *trans*-autophosphorylation. In turn, autophosphorylation activates the C-terminal RNase domain to catalyze site-specific cleavage of the mRNA encoding the XBP1 transcription factor, excising a 26 nucleotide intervening region^[@R13],[@R14]^. Religation of cleaved XBP1 mRNA and translation in the shifted open-reading frame produces the XBP1s (s = spliced) transcription factor, whose gene targets allow the ER to adapt to protein-folding stress.

Genetic analysis shows that activation of IRE1α's RNase is normally dependent on kinase autophosphorylation^[@R6]^, but we previously identified an unusual relationship between these two domains that allows specific ligands of the kinase domain to bypass the autophosphorylation requirement and trigger RNase activation through ligand occupancy alone^[@R15]^. For instance, the orthogonal ATP-competitive inhibitor 1NM-PP1 rescues RNase activity of IRE1α mutants that lack kinase activity^[@R7],[@R8],[@R15]^. Other ligands that interact with the ATP-binding site of wild-type (WT) IRE1α also activate the RNase directly. For example, the ATP-competitive inhibitor APY29 and the clinically-approved drug sunitinib activate the RNase of yeast^[@R16]^ and murine IRE1α^[@R7]^.

Given the ability to allosterically activate IRE1α's RNase through its kinase domain, we hypothesized that it may be feasible to also inhibit the RNase through the same kinase domain, but with a different class of kinase inhibitors. Two classes of kinase inhibitors---called types I and II---have been identified, which stabilize alternate kinase active site conformations in numerous protein kinase targets^[@R17]^. Here we show that a known type I kinase inhibitor and a novel type II kinase inhibitor both shut down IRE1α *trans*-autophosphorylation, but have divergent effects on its RNase to activate or inactivate catalytic activity, respectively. Our findings demonstrate that IRE1α RNase activity can be either up or downregulated through selective targeting of its kinase domain to control UPR signaling, and predict that it may be possible to pharmacologically modulate other kinase-coupled enzymes in a similar way.

Results {#S1}
=======

Divergent modulation of the IRE1α's RNase activity {#S2}
--------------------------------------------------

A co-crystal structure of yeast IRE1 bound with APY29---a predicted type I kinase inhibitor---shows that the kinase catalytic domain is in an active conformation, which is a conformation typically adopted by protein kinases when bound to ATP and other type I inhibitors ([Fig. 1a](#F1){ref-type="fig"})^[@R16],[@R18]^. Moreover, two additional co-crystal structures of yeast IRE1 and human IRE1α bound with ADP show that the kinase domain is similarly in an active conformation^[@R18]--[@R20]^. By stabilizing IRE1α's kinase in the active conformation, these type I inhibitors act as ligands that allosterically activate its adjacent RNase domain. Therefore, we postulated that it might be possible to stabilize IRE1α's kinase domain in an alternative conformation, and in so doing disable its RNase activity. To test this notion, we employed a class of small-molecule kinase inhibitors that have been described to selectively stabilize the inactive conformation of the ATP-binding site (type II inhibitors) for a variety of kinases; examples include the clinically-approved drugs imatinib and sorafenib^[@R17],[@R21],[@R22]^. The inactive ATP-binding site conformation stabilized by type II inhibitors is characterized by outward movement of the catalytically-important Asp-Phe-Gly (DFG) motif, and is therefore called the DFG-out conformation ([Fig. 1a](#F1){ref-type="fig"})^[@R17],[@R23]^. In contrast, in all three co-crystal structures of IRE1 mentioned previously, the kinase domain adopts the DFG-in conformation^[@R16],[@R19],[@R20]^.

Therefore, we hypothesized that stabilizing an inactive ATP-binding site conformation of IRE1α with type II inhibitors may have inhibitory rather than activating allosteric effects on the RNase. To this end, several previously characterized type II inhibitors were screened for their ability to block the RNase activity of a recombinant soluble human IRE1α mini-protein construct containing the kinase/RNase domains---called IRE1α\* ([Supplementary Results, Supplementary Figs. 1 and 2](#SD1){ref-type="supplementary-material"}). Since IRE1α\* is basally autophosphorylated, its RNase is autoactive, and can be assayed using a FRET-quenched XBP1 RNA mini-substrate^[@R7]^ ([Fig. 1b](#F1){ref-type="fig"}). While all the compounds we tested with this assay contain the core binding elements predicted to stabilize the DFG-out conformation, only one ligand, **1**, demonstrated measurable inhibition of IRE1α\*'s RNase activity ([Fig. 1c,d](#F1){ref-type="fig"}). **1** is a pyrazolopyrimidine-based inhibitor that has been shown to stabilize the DFG-out conformation of the non-receptor tyrosine kinases Src and Abl. Based on the co-crystal structure of **1** bound to Src (PDB: 3EL8)^[@R24]^, proposed contacts with IRE1α are shown in [Fig. 1a](#F1){ref-type="fig"}.

Despite its modest activity, **1** served as a promising starting point to develop more potent allosteric RNase inhibitors. A number of similar analogs were generated and tested for RNase inhibition. While most modifications of **1** were deleterious, replacing the pyrazolopyrimidine scaffold with an imidazopyrazine core provided a significant increase in overall potency (compound **2**, [Fig. 1c,d](#F1){ref-type="fig"}). Furthermore, substituting the 4-anilino group at the *C*-3 position of **2** with a naphthylamine moiety provided **3**, the most potent compound identified in this study. Notably, **3** inhibits XBP1 RNA cleavage to a similar degree as STF-083010, an imine-based small molecule that directly inhibits the IRE1α RNase through covalent modification^[@R25]^.

Similar to APY29, **3** demonstrates dose-dependent reduction of IRE1α\* kinase autophosphorylation *in vitro* ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Thus, although **3** and APY29 are both IRE1α\* kinase inhibitors, they demonstrate opposing effects on its RNase activity, with APY29 acting as a slight activator. To further characterize the differences between the two kinase inhibitors, we generated a version of IRE1α\* with low basal RNase activity by using λ-phosphatase (λ-PPase) to remove activating phosphates from the enzyme ([Fig. 2b](#F2){ref-type="fig"} and [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). As expected, the dephosphorylated variant of IRE1α\* (dP-IRE1α\*) has significantly lower basal RNase activity than IRE1α\*; incubating dP-IRE1α\* with increasing APY29 concentrations progressively restores its ability to cleave the XBP1 mini-substrate, plateauing at \~60% of the levels of IRE1α\* ([Figs. 2c,d](#F2){ref-type="fig"} and [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). In contrast, **3** suppresses the residual RNase activity of dP-IRE1α\*.

Competition experiments were performed to further explore the opposing effects of APY29 and **3**. Increasing concentrations of APY29 progressively reverse IRE1α\* RNase inhibition caused by a fixed concentration of **3** ([Fig. 2e](#F2){ref-type="fig"}). On the other hand, increasing concentrations of **3** restore RNase inhibition in the setting of a fixed concentration of APY29, with an expected increase in the IC~50~ ([Fig. 2e](#F2){ref-type="fig"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). As predicted, APY29 cannot rescue direct inhibition caused by the covalent RNase modifier STF-083010. Taken together, these results strongly suggest that APY29 and **3** are exerting their opposing effects on RNase activity through the same binding site.

The drug sunitinib is a promiscuous type I inhibitor that has been shown to inhibit the kinase activity of yeast and human IRE1α^[@R16],[@R19]^. To investigate the differences between **3** and other ATP-competitive inhibitors of IRE1α, we further characterized the interaction of sunitinib with our IRE1α\* and dP-IRE1α\* constructs. As expected, sunitinib is a dose-dependent inhibitor of the autophosphorylation activity of IRE1α\* ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}). In addition, sunitinib activates the RNase activity of dP-IRE1α\*, which is consistent with its type I pharmacophore ([Supplementary Fig. 8b](#SD1){ref-type="supplementary-material"}). Therefore, both APY29 and sunitinib stabilize an ATP-binding site conformation that activates the RNase domain of IRE1α. Like APY29, increasing amounts of sunitinib are able to rescue the RNase activity of IRE1α\* in the presence of a fixed concentration of **3** ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}). Together, these results show that **3** opposes the stereotypic RNase activation demonstrated by various type I ATP-competitive inhibitors of IRE1α.

Analysis of the 3-IRE1α and APY29-IRE1α interactions {#S3}
----------------------------------------------------

To further confirm that AYP29 and **3** are exerting their opposing effects through the same ATP-binding site, we next turned to a series of biochemical footprinting experiments^[@R26],[@R27]^. Specifically, the accessibility of three native cysteine residues within human IRE1α (Cys572, Cys645, and Cys715) to alkylating agents in the presence or absence of APY29 and **3** was determined ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). For these studies, electrophilic isotope-coded affinity tag (ICAT) reagents were used to allow a ratiometric and, therefore, quantitative comparison of alkylation rates^[@R27]^. As Cys645 and Cys715 are located within the ATP-binding cleft of IRE1α, the accessibility of these residues would be expected to be affected by ligands that occupy this site, while Cys572 is a solvent-exposed residue located on the top of the *N*-terminal lobe of the kinase. Consistent with both APY29 and **3** occupying the ATP-binding site of IRE1α, Cys645, which is located in the kinase hinge region, is highly shielded from alkylating agents in the presence of either inhibitor ([Fig. 3a](#F3){ref-type="fig"}). In contrast, these inhibitors exert opposing effects on the accessibility of Cys715, with APY29 slowing the rate of alkylation and **3** increasing it. Cys715 is located in the activation loop of IRE1α (two residues C-terminal to the DFG-motif) and the divergent influence of APY29 and **3** on this residue is concordant with these ligands stabilizing different conformations of the activation loop ([Fig. 3b](#F3){ref-type="fig"}). As expected, no detectable difference in the accessibility of Cys572, which is distal to the kinase active site of IRE1α, is observed in the presence of either inhibitor ([Fig. 3c](#F3){ref-type="fig"}).

Next, we performed molecular docking experiments to obtain a better understanding of how **3** and APY29 interact with the ATP-binding site of human IRE1α. A model of the DFG-in ATP-binding site conformation was generated from a co-crystal structure of human IRE1α bound to ADP (PDB code 3P23, chain A)^[@R19]^. As a structure of IRE1α in the DFG-out conformation has not yet been described, a homology model of this conformation was generated by using the activation loop of another kinase---the tyrosine kinase Abl2---as a template. Both the DFG-in and DFG-out models were optimized using multi-step all-atom minimization and explicit water molecular dynamics (MD) simulations^[@R28]^. Predictably, the docked structure of APY29 bound to the DFG-in conformation of human IRE1α is similar to that of this ligand bound to the yeast IRE1 enzyme ([Supplementary Fig. 10](#SD1){ref-type="supplementary-material"})^[@R16]^. The pyrazole ring of APY29 forms hydrogen bonds with the kinase hinge region and the pyrimidine moiety occupies the adenine pocket. Attempts to obtain a favorable pose of APY29 bound to the DFG-out conformation of IRE1α were unsuccessful, which is consistent with the ability of this ligand to exclusively stabilize the active conformation of the ATP-binding site.

The most favorable docking pose for **3** bound to the DFG-out conformation of IRE1α is shown in [Figure 3d](#F3){ref-type="fig"}. In this pose, the imidazopyrazine ring of this ligand forms two hydrogen bonds with the hinge region and occupies the adenine pocket. The bulky naphthyl ring of **3** adopts an almost orthogonal conformation relative to the core scaffold and stacks against the Ile gatekeeper residue. Like other type II inhibitors, the trifluoromethylphenyl moiety of **3** occupies the hydrophobic pocket created by movement of the Phe sidechain in the DFG-motif. While **3** is well accommodated in the DFG-out conformation of human IRE1α, no favorable poses were observed for this inhibitor bound to the DFG-in conformation. Indeed, our docking studies predict that the only way that **3** can bind to IRE1α without movement of the DFG motif in the activation loop is if the inhibitor disrupts canonical interactions with the hinge region of the kinase.

To further experimentally test our docking model, we generated analogs of **3** that contain structural elements predicted to lower inhibitor potency (compounds **4** and **5**, [Fig. 1d](#F1){ref-type="fig"}). **4** contains an *N*-methyl group that would be predicted to disrupt its interaction with the hinge region of IRE1α, and the amide linkage of **5** should not allow the trifluoromethylphenyl moiety to form as favorable interactions with the hydrophobic pocket created by movement of the DFG-motif. Consistent with our model, both **4** and **5** show a markedly diminished ability to inhibit the RNase activity of IRE1α compared to **3** ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}).

3 and APY29 divergently affect IRE1α oligomerization {#S4}
----------------------------------------------------

Self-association of kinase/RNase monomers has been reported to increase RNase activity as dimers and/or higher-order oligomers form in yeast and mammalian IRE1 proteins^[@R11],[@R16],[@R19]^. Although it has not been resolved whether IRE1α RNase activation requires kinase dimerization or high-order oligomerization per se, it is generally accepted that monomeric species are inactive; furthermore, the degree of order may correlate directly with activity^[@R16]^. Thus we used APY29 and **3** to test the prediction that they would divergently affect the oligomerization state of human IRE1α as a basis for their opposing effects on its RNase activity. Specifically, we predicted that RNase activators should drive monomers into higher-order species (dimers and perhaps oligomers) from baseline. To test this prediction, increasing concentrations of IRE1α\* were incubated with either DMSO, or saturating concentrations of APY29 or **3** and the ratio of oligomeric---defined as all species greater than monomers (mostly dimers) ---to monomeric IRE1α was determined ([Fig. 4a](#F4){ref-type="fig"}). In the absence of ligands, IRE1α\* shows a concentration-dependent increase in the oligomer/monomer ratio. The presence of APY29 further enhances---whereas **3** decreases---this concentration-dependent increase in the IRE1α\* oligomer/monomer ratio. Taken together, our *in vitro* data support a model in which these two classes of kinase inhibitors divergently modulate IRE1α\* RNase activity by exerting opposing effects on the oligomerization state of the enzyme ([Fig. 4b](#F4){ref-type="fig"}).

IRE1α mutants show increased sensitivity to 3 {#S5}
---------------------------------------------

Having used a truncated form of IRE1α for all our *in vitr*o studies, we next turned to cell-based experiments to test whether we could replicate divergent modulation of the full-length IRE1α transmembrane protein with the two classes of kinase inhibitors. We first tested and confirmed the on-target effects of **3** using IRE1α chemical-genetic systems we had previously developed^[@R7]^. Specifically, we employed tetracycline-inducible isogenic T-REx 293 stable cell lines expressing either WT or a "holed" IRE1α gatekeeper mutant^I642A^ to determine whether **3** is able to block the RNase activity of IRE1α *in vivo*. Induced with doxycycline (Dox), the transgenic WT-IRE1α or IRE1α^I642A^ spontaneously cluster in the ER, *trans*-autophosphorylate and splice XBP1 mRNA, without requiring upstream ER stress ([Fig. 5a](#F5){ref-type="fig"} and [Supplementary Figs. 12 and 13](#SD1){ref-type="supplementary-material"}). As expected, **3** inhibits autophosphorylation and XBP1 mRNA splicing in the WT cell lines ([Supplementary Fig. 13a,b](#SD1){ref-type="supplementary-material"}). Consistent with these inhibitory effects occurring through a direct interaction with IRE1α, control compound **4** does not affect either of these parameters, even at the highest concentration tested ([Supplemental Fig. 13c](#SD1){ref-type="supplementary-material"}). Furthermore, we hypothesized that the enlarged ATP-binding pocket of IRE1α^I642A^ would better accommodate the bulky C-3 substituent of **3**, leading to enhanced sensitivity. Indeed, our docking studies suggest that the naphthyl ring of **3** is able to occupy a hydrophobic pocket that is accessible in IRE1α^I642A^ and not the wild type protein ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}). Confirming this notion, low nanomolar concentrations of **3** are sufficient to completely block autophosphorylation and XBP1 splicing through this mutant ([Fig. 5a,b](#F5){ref-type="fig"} and [Supplemental Figs. 15 and 16](#SD1){ref-type="supplementary-material"}). Furthermore, increasing concentrations of the type I "bumped" inhibitor 1NM-PP1, which is selective for mutant kinases that contain Ala or Gly gatekeeper residues, is able to rescue the RNase activity of IRE1α^I642A^ in the presence of **3** ([Fig. 5c](#F5){ref-type="fig"} and [Supplemental Fig. 17](#SD1){ref-type="supplementary-material"}).

Our data suggest a model for IRE1α^I642A^, which can be activated merely through overexpression to basally splice \~50% of cellular XBP1 mRNA, that 1NM-PP1 further increases---while **3** reduces---the activity of the RNase ([Supplemental Fig. 18](#SD1){ref-type="supplementary-material"}). We propose that these divergent effects proceed from the stabilization of the kinase active site in two distinct modes by these inhibitors, with 1NM-PP1 acting on the "holed" IRE1α^I642A^ kinase in a similar fashion as APY29 does for WT IRE1α. In summary, the type II pharmacophore **3** likely enforces an inactive kinase conformation in IRE1α^I642A^, and as it does with WT IRE1α. Furthermore, **3** may stabilize monomeric IRE1α^I642A^, while 1NM-PP1 may promote oligomerization, as APY29 does for the WT IRE1α ([Fig. 4b](#F4){ref-type="fig"}).

3 blocks both enzymatic activities of IRE1α *in vivo* {#S6}
-----------------------------------------------------

To further explore how IRE1α modulators affect the kinase and RNase activities of endogenous IRE1α under ER stress, we next turned to *in vivo* studies using INS-1 rat insulinoma cell lines, which are derived from insulin-producing pancreatic β-cell tumors and contain large well-developed ERs. These cells were treated with the ER SERCA ATPase pump inhibitor, thapsigargin (Tg), to induce ER stress and IRE1α activation at levels causing \~50% splicing of cellular XBP1 mRNA ([Fig. 6a](#F6){ref-type="fig"} and [Supplemental Fig. 19](#SD1){ref-type="supplementary-material"}). Recapitulating our *in vitro* results, **3** and APY29 demonstrate opposing dose-dependent effects on ER stress-induced activation of the RNase of endogenous IRE1α ([Fig. 6a](#F6){ref-type="fig"} and [Supplemental Fig. 19](#SD1){ref-type="supplementary-material"}). Furthermore, **3** abrogates IRE1α autophosphorylation at a similar concentration as it blocks RNase activity ([Fig. 6b,c](#F6){ref-type="fig"} and [Supplemental Figs. 20 and 21](#SD1){ref-type="supplementary-material"}). Control compound **4** does not block the splicing of XBP1 mRNA ([Fig. 6d](#F6){ref-type="fig"} and [Supplemental Fig. 22](#SD1){ref-type="supplementary-material"}). Consistent with its *in vitro* activity, the type I inhibitor sunitinib is able to partially inhibit the kinase activity of IRE1α, but has no effect on the RNase activity of this enzyme ([Fig. 6b,c](#F6){ref-type="fig"} and [Supplemental Figs. 20 and 21](#SD1){ref-type="supplementary-material"}) at the concentrations tested. The RNase inhibitor STF-083010 was also tested in INS-1 cells that had been treated with Tg. As expected, this compound inhibits XBP1 splicing in a dose-dependent manner, but does not prevent IRE1α auto-phosphorylation ([Fig. 6b,c](#F6){ref-type="fig"} and [Supplemental Figs. 20 and 21](#SD1){ref-type="supplementary-material"}). Therefore, **3** is the only compound identified to date that has the ability to block both enzymatic activities of IRE1α, both *in vitro* and *in vivo* ([Fig. 6e](#F6){ref-type="fig"}).

Discussion {#S7}
==========

Recent studies show that the duration and amplitude of UPR activation powerfully affects both cell function and fate^[@R7],[@R8],[@R29],[@R30]^. Indeed, many cell-degenerative diseases such as diabetes mellitus feature increased ER stress and UPR activation in affected cells^[@R3],[@R31],[@R32]^. These same markers are evident in a wide range of solid and hematopoietic malignancies^[@R33]^. To properly ascertain the role of the UPR in these disease contexts will require development of tool compounds that target critical nodes in the UPR in both positive and negative directions. The master UPR regulator IRE1α, which controls cell fate under ER stress, offers two enzymatic targets that could be modulated with small molecules. In this work, we exploited the unusual mechanistic relationship between these two catalytic domains to inhibit the RNase from a distance by inhibiting the kinase.

Starting with known pharmacophores that stabilize an inactive conformation in other protein kinases, we optimized a type II inhibitor lead to produce **3**. Despite inhibiting IRE1α kinase autophosphorylation similarly to the type I inhibitor APY29, **3** inhibits XBP1 mRNA splicing, even during ER stress. Consistent with competition studies, footprinting experiments strongly suggest that **3** and APY29 bind to the same ATP-binding pocket. However, these same footprinting experiments indicate that these inhibitors cause divergent effects on the activation loop of IRE1α, and support a model in which **3** and APY29 promote distinct, mutually exclusive, movements of the DFG-motif contained within the activation loop.

The aforementioned experiments, combined with modeling studies, lead to a parsimonious model of IRE1α modulation by kinase inhibitors ([Fig. 6e](#F6){ref-type="fig"}) that posits that the protein can adopt either a canonical DFG-in or a DFG-out conformation, as is seen with other kinases under the influence of types I and II inhibitors, respectively. However, while for other kinases these two distinct modes of inhibition stereotypically shut down kinase function, for the multi-domain kinase, IRE1α, the two inhibition modes have opposite and divergent results on the attached RNase activity. To our knowledge, this ability to modulate a second catalytic activity in a multi-domain kinase in two different directions with distinct classes of ATP-competitive inhibitors has not been reported to date. We expect that this ability may be extended to many of the other known multi-domain kinases.

Intriguingly, opposite effects on oligomeric state were found using the two compounds: while type I inhibitors increase the dimeric and possibly oligomeric state of IRE1α and the catalytic activity of the RNase, type II inhibitors decrease both in tandem. Given previous reports of a direct mechanistic relationship between the degree of order and RNase activity in IRE1 proteins^[@R16]^, we speculate that the inactive conformation that **3** stabilizes in IRE1α promotes the monomeric state.

It is of course conceivable that a different, previously unidentified active site conformation is adopted in the presence of **3**; to fully resolve this particular point in the future will require atomic level co-crystal structures. Regardless, the particular kinase active site conformation stabilized by **3** has the unique and novel property of preserving the mechanistic coupling between the kinase and the RNase in IRE1α, allowing full inhibition of both activities in concert. We propose that this represents a new alternative to aldehyde-based covalent inhibitors of the RNase such as STF-083010 (or another recently reported compound called 4µ8C^[@R34]^), which leave kinase autophosphorylation and oligomerization intact. In contrast to the action of direct RNase inhibitors, any biological signaling through the kinase that is dependent on phosphorylation of non-autonomous substrates or kinase-mediated scaffolding should be simultaneously quenched with type II kinase inhibitors.

In summary, the ability to now inhibit the effector RNase domain of IRE1α with type II kinase inhibitors complements our previous ability to activate the RNase with type I inhibitors, independent of upstream ER stress, establishing opposite directions of control over this master UPR regulator. Thus, type II kinase inhibitors of IRE1α will expand on a toolkit that includes chemical-genetic systems to test and validate the UPR's role in ER stress-related diseases. While **3** is not completely selective for IRE1α over other protein kinases, this compound serves as a starting point for the generation of more potent and selective inhibitors that may eventually be developed into disease-modifying drugs for ER stress-related disorders. Moreover, the ability to toggle the IRE1α RNase on and off through its kinase domain may serve as a precedent for pharmacologically targeting the many other kinase-coupled enzymes present in eukaryotes.

Methods {#S8}
=======

Synthesis and characterization of probes are described in the [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

Expression and purification of IRE1α\* and dP-IRE1α\* {#S9}
-----------------------------------------------------

A construct containing the cytosolic kinase and RNase domains of human IRE1α (residues 469--977, IRE1α\*) was expressed in SF9 insect cells by using Bac-to-Bac baculovirus expression system (Invitrogen) with a 6-His-tag at the N-terminus, and purified with a Ni-NTA (Qiagen) column. To generate dP-IRE1α\*, basal phosphorylation sites were removed by incubating IRE1α\* with λ-PPase (NEB) at a molar ratio of 5:1 (IRE1α\*: λ-PPase) in 50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM MnCl~2~, 2 mM DTT, 0.01% Brij 35 for 40 min at RT. Dephosphorylation was verified by immunoblotting with an anti-phosphoIRE1α antibody.

Kinase assays {#S10}
-------------

Inhibitors (initial concentration = 80 µM, 2-fold serial dilutions) were incubated with IRE1α\* in cleavage buffer (20 mM Hepes at pH 7.5, 0.05% Triton X100, 50mM KOAC, 1 mM Mg(OAC)~2~, 1 mM DTT) for 20 min, followed by incubation with 10 µCi \[γ-^32^P\]ATP (3000 Ci/mmol, Perkin Elmer) at RT for 30 min. Samples were then separated by SDS-PAGE, and autoradiographed. The auto-phosphorylation level were quantified by setting the band intensity of IRE1α\* without compound treatment as 1 and the background as 0.

In vitro RNase assay {#S11}
--------------------

5'FAM-3'BHQ-labeled XBP1 single stem-loop minisubstrate (5'FAM-CUGAGUCCGCAGCACUCAG-3'BHQ) was purchased from Dharmacon. 0.2 µM IRE1α\* or dP-IRE1α\* were incubated with inhibitors or DMSO for 20 min in cleavage buffer, followed by incubation with 3 µM RNA substrate for 5 min. The reaction was quenched by adding urea to a final concentration of 4 M, and the fluorescence was detected on a SpectraMax M5 microplate reader (Molecular Devices) with excitation and emission wavelengths of 494 nm and 525 nm, respectively. The fluorescence intensities were normalized by setting the signal for the reaction with IRE1α\* and DMSO to 1 and the reaction without IRE1α\* to 0. The cleavage products were also resolved by urea PAGE after phenol/chloroform extraction and ethanol precipitation. Internally ^32^P-labelled mouse XBP1 RNA was also used as a substrate, as described^[@R7]^.

ICAT Footprinting {#S12}
-----------------

Heavy and light iodonated ICAT reagents were made as described by Underbakke et al^[@R27]^. Purified human Ire1α was exchanged into 50 mM Tris (pH 8.0), 50 mM KCl, 5 mM MgCl~2~, and 0.5 mM TCEP. One 3 µM stock solution was divided into three solutions, and each was mixed with either DMSO, APY29, or **5** to yield solutions containing 1% DMSO and 20 µM of inhibitor. Heavy labeling reagent was added to the protein solutions, and 25 µL aliquots were taken at specified times and quenched with excess DTT. Samples were precipitated with 0.2% sodium deoxycholate and 10% trichloroacetic acid on ice for 10 min. The mixtures were centrifuged at 4 °C for 15 min, and pellets were washed with cold acetone. The pellets were then resuspended in 30 µL of 200 mM Tris (pH 8.0), 7 M urea, and 2.4 mM light labeling reagent, and incubated in the dark for 30 min. The solutions were diluted with 210 µL 200 mM Tris (pH 8.0), 5.7 mM CaCl~2~, 0.5 µg porcine trypsin (TPCK treated, Sigma), and 125 ng GluC (Roche), and incubated at room temperature overnight. Samples (0.3 pmol) were injected onto a Thermo Scientific Dionex Acclaim Pepmap100 NanoLC capillary column (C~18~, 150 mm length, I.D. 75 µm, 3 µm particle size) connected inline to a Finnigan LCQ mass spectrometer. Peptides of interest were identified by MS/MS data (Sequest), and corresponding XIC peaks were integrated. Alkylation curves were fit using GraphPad Prism software (Binding -- Kinetics, Dissociation -- One-phase exponential decay).

IRE1α\* Cross-linking to determine oligomer to monomer ratio {#S13}
------------------------------------------------------------

Increasing concentrations of IRE1α\* (0.49--30 µM) were incubated with DMSO, **3** (200 µM), or APY29 (200 µM) for 20 min, then cross-linked by adding 250 µM disuccinimidyl suberate (DSS) (Pierce) for 1 hr at RT in cleavage buffer. The reaction was quenched by addition of 50 mM Tris-HCl (pH 7.5). The samples were then boiled, resolved on SDS-PAGE, and immunoblotted for IRE1α with an anti-IRE1α antibody, (visualization and quantification with a LI-COR Odyssey scanner).

Cell culture and XBP1 mRNA splicing {#S14}
-----------------------------------

INS-1 cells were grown in RPMI, 10% fetal calf serum, 1 mM sodium pyruvate, 10 mM HEPES, Pen/strep, 2 mM glutamine and 50 µM β-mercaptoethanol. T-REx 293 IRE1α or IRE1α^I642A^ were grown in DME H-21 with 10% fetal calf serum and Pen/strep. After 1 hr incubation with compounds, INS-1 cells were treated with 6 nM thapsigargin for 4 hrs, and T-Rex 293 IRE1α-expressing cells were treated with 1 µM Dox for 8 hrs. The RNA was then extracted using RNeasy Mini Kit (Qiagen), and reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen). XBP1 splicing was performed as previously described^[@R7]^. Primers used: sense primer rXBP 1.3S (5'- AAACAGAGTAGCAGCACAGACTGC-3") and antisense primer rXBP 1.2AS (5'- GGATCTCTAAGACTAGAGGCTTGGTG-3') for INS-1 cell line, while sense primer mXBP1.3S (5'-AAACAGAGTAGCAGCGCAGACTGC-3') and antisense primer mXBP1.2AS (5'-GGATCTCTAAAACTAGAGGCTTGGTG-3') for T-Rex 293 cell line. PCR products were resolved on 2.5% agarose gels, stained with EtBr, and quantified by ImageJ.

Statistical analysis {#S15}
--------------------

All experiments were performed in triplicate, unless otherwise specified. Results are shown as mean ± standard deviation (SD).

Other methods {#S16}
-------------

Detailed information is available in the [Supplementary Methods](#SD1){ref-type="supplementary-material"}.
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![Interaction of ATP-competitive inhibitors with the bifunctional kinase/RNase, IRE1α\
(**a**) Proposed binding modes of type I and type II kinase inhibitors with the ATP-binding pocket of IRE1α. Left panel shows the contacts the type I inhibitor APY29 forms with yeast IRE1α (PDB code 3SDJ)^[@R18]^. The right panel shows the proposed contacts a type II inhibitor **1** forms with IRE1α based on the co-crystal structure of the same inhibitor bound to Src (PDB code 3EL8) (also see [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). (**b**) XBP1 RNA minisubstrate assay used for screening IRE1α modulators. The recombinant human IRE1α---IRE1α\*---used in the assay spans residues 469--977, which includes the cytosolic kinase and RNase domains. Cleavage of the 5'FAM-3'BHQ-labeled XBP1 minisubstrate by IRE1α\* results in FRET-dequenching. (**c**) Endpoint fluorescence of IRE1α\* catalyzed cleavage reaction of XBP1 minisubstrate in the presence of varying concentrations of inhibitors, or DMSO. STF-083010 is an imine-based compound that covalently inhibits the RNase domain. Relative fluorescence intensity is scaled to the signal observed with IRE1α\* (1.0), or without IRE1α\* (0). (mean ± SD, n = 3). (**d**) Structures of the type II kinase inhibitors used in this study.](nihms407018f1){#F1}

![APY29 and 3 divergently modulate the RNase activity and oligomerization state of IRE1α\*\
(**a**) Inhibition of IRE1α\* autophosphorylation *in vitro* by APY29 and **3**. Normalized autophosphorylation levels and IC~50~ values for both compounds are shown. (**b**) λ-PPase treatment of IRE1α\* produces dephosphorylated IRE1α\* (dP-IRE1α\*). Immunoblots using anti-IRE1α and anti-phospho IRE1α antibodies are shown. (**c**) RNase activities of IRE1α\* and dP-IRE1 α\* under varying concentrations of APY29 or **3** per the assay of [Figure 1b](#F1){ref-type="fig"}. EC~50~ values were determined by fitting normalized fluorescence intensities (mean ± SD, n = 3). (**d**) Urea PAGE of XBP1 mini-substrate cleavage by IRE1α\* and dP-IRE1α\* with and without **3** or APY29. (**e**) RNase competition assays between APY29 and **3**. The red line shows IRE1α\* RNase activity under fixed **3** and varying APY29 concentrations. The black line shows IRE1α\* RNase activity under fixed APY29 and varying **3** concentrations. The blue line shows IRE1α\* RNase activity under fixed STF-083010 and varying APY29 concentrations (mean ± SD, n = 3).](nihms407018f2){#F2}

![Characterization of 3\'s interaction with the ATP-binding site of IRE1α\
Results of the ICAT footprinting experiments with IRE1α\*. Alkylation rates were measured in the presence of DMSO (black), APY29 (blue) (20 µM), or **3** (red) (20 µM) (mean ± SD, n = 3). (**a**) Alkylation rate of Cys572. (**b**) Alkylation rate of Cys645. (**c**) Alkylation rate of Cys715. (**d**) A molecular model of **3**\'s interaction with the ATP-binding site of IRE1α (grey). IRE1α is in the DFG-out inactive conformation. The imidazopyrazine ring of **3** occupies the adenine pocket and the 3-trifluoromethylurea occupies the DFG-out pocket. No favorable poses for **3** bound to the DFG-in conformation of IRE1α could be determined.](nihms407018f3){#F3}

![APY29 and 3 differentially affect the oligomerization state of IRE1α\*\
(**a**) Left panels shows immunoblots of IRE1α\* after treatment with the crosslinker DSS (250 µM). Increasing concentrations of IRE1α\* were incubated with DMSO, APY29 (200 µM) or **3** (200 µM). The right panel shows quantitation of the ratios of oligomeric to monomeric IRE1α\* (**b**) Model of how type I and type II kinase inhibitors affect the RNase activities and oligomeric states of IRE1α\* and dP-IRE1α\*.](nihms407018f4){#F4}

![Chemical-genetic modulation of IRE1α kinase and RNase activity *in vivo*\
(**a**) Anti-total and anti-phospho IRE1α immunoblots of T-Rex 293 cells expressing "holed" IRE1α^I642A^ under Doxycycline (Dox) control. Cells were pre-treated for 1 hr with **3** at indicated concentrations, then induced with Dox (1 µM) for 8 hrs. Plots show normalized phosphorylation levels and ratios of spliced XBP1 mRNA under varying concentrations **3** (mean ± SD, n \>= 3). (**b**) Quantification of the XBP1 cDNA amplicons from the cells described in (**a**). EtBr-stained agarose gels are shown in [Supplementary Figure 16](#SD1){ref-type="supplementary-material"} (**c**). Competition between the "bumped" kinase inhibitor 1NM-PP1 and **3** against IRE1α^I642A^. T-Rex 293 cells expressing IRE1α^I642A^ were pre-treated for 1 hr with **3** (1 µM) ± varying concentrations 1NM-PP1 before Dox induction (1 µM) for 8 hrs. Quantification show ratios of spliced XBP1 mRNA as a function of **3** and 1NM-PP1 concentrations. \[XBP1^S^ = spliced XBP1; XBP1^U^ = unspliced XBP1\]](nihms407018f5){#F5}

![Divergent modulation of endogenous IRE1α RNase activity under ER stress with types I and II kinase inhibitors\
(**a**) Quantification of EtBr-stained agarose gel of XBP1 complementary DNA (cDNA) amplicons from INS-1 cells pre-treated for 1 hr with **3** or APY29 at indicated concentrations, followed by Tg (6 nM) for 4 hrs. Ratios of XBP1^S^ over (XBP1^S^ + XBP1^U^) are plotted (mean ± SD, n = 3). Gels are shown in [Supplemental Figure 19](#SD1){ref-type="supplementary-material"}. (**b**) Anti-total and anti-phospho IRE1α immunoblots using extracts from INS-1 cells pre-treated for 1 hr with **3**, sunitinib or STF-083010 at indicated concentrations, followed by Tg (6 nM) for 2 hrs. (**c**) Quantification of EtBr-stained agarose gel of XBP1 complementary DNA (cDNA) amplicons from the INS-1 cells described in (**b**). Gels are shown in [Supplemental Figure 20](#SD1){ref-type="supplementary-material"}. (**d**) EtBr-stained agarose gel of XBP1 cDNA amplicons from INS-1 cells pre-treated for 1 hr with **4** at indicated concentrations, followed by Tg (6 nM) for 4 hrs. (**e**) Model of how type I kinase inhibitors (APY29 or sunitinib), type II kinase inhibitors (**3**), and RNase inhibitors (STF-083010) modulate the enzymatic activities of WT IRE1α. APY29 inhibits IRE1α *trans*-autophosphorylation but promotes oligomerization and activates the RNase domain. STF-083010 inhibits the RNase activity of IRE1α but does not affect kinase activity or the overall oligomerization state. **3** inhibits both the kinase and RNase domains of IRE1α and stabilizes the monomeric form. \[Please note that these cartoons are not meant to differentiate between the relative orientations of monomer subunits in IRE1α.\]](nihms407018f6){#F6}
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